1/9/2020 7:01:42 AM
Regeneron Announces Encouraging Garetosmab Phase 2 Results In Patients With Ultra-Rare Debilitating Bone Disease
12/10/2019 8:40:08 AM
Sanofi And Regeneron To Restructure Antibody Collaboration For Kevzara And Praluent
12/10/2019 8:31:53 AM
Regeneron, Sanofi To Restructure Antibody Collaboration For Kevzara, Praluent
12/5/2019 7:02:07 AM
Regeneron Reports Positive Topline Phase 2 Data With Anti-C5 Antibody Pozelimab In Patients With Rare Blood Disorder
11/6/2019 7:06:05 AM
Regeneron, Vyriad Announce Strategic Agreement For Development Of New Oncolytic Virus Treatments For Cancer
11/5/2019 6:43:00 AM
Regeneron Updates On Phase 3 Libtayo Development Program In Advanced Non-small Cell Lung Cancer
11/5/2019 6:37:50 AM
Regeneron Pharmaceuticals (REGN) Announces $1 Bln Stock Buyback
11/5/2019 6:31:30 AM
Regeneron Q3 GAAP EPS $5.86; Non-GAAP Diluted EPS $6.67
10/29/2019 8:21:42 AM
Regeneron Pharma And Sanofi: EC Approves New Indication For Dupixent In Chronic Rhinosinusitis With Nasal Polyposis